PhytoCare: Journal of Pharmacology and Natural Remedies
Vol. 1 No. 4 April 2025
E-ISSN: 3089-6444
Open Access: https://journals.ai-mrc.com/phytocare

Phenomenological Exploration of Perceptions, Emotional Responses, and Ethical Considerations in Biotechnology-Based Drug Development

Indarta Priyana
Universitas Pasundan, Indonesia
Indarta.priyana@unibi.com

Article Info

Article history:
Received 28-02-2025
Revised 26-03-2025
Accepted 17-04-2025

Keyword:
Biotechnology-Based Drug Development, Phenomenological Exploration, Risk Perception, Ethical Considerations, Personal Experiences, Bioinformatics in Drug Development..

ABSTRACT

Biotechnology-based drug development has significantly advanced medical treatment but also presents unique challenges and ethical concerns for researchers and clinicians While much of the existing research focuses on technical and regulatory aspects, there is a lack of understanding regarding the subjective experiences of those directly involved in the field. Specifically, the emotional, ethical, and personal dimensions of biotechnology development remain underexplored. This study aims to address this gap by investigating the lived experiences of biotechnology professionals and exploring how they perceive the risks and benefits of drug development. Using a phenomenological approach, this research delves into the personal, emotional, and ethical experiences of participant involved in biotechnology drug development. Through in-depth interviews with 15 participants, thematic analysis revealed key themes, including the balance between risk and reward, challenges in identifying natural compounds, and the role of bioinformatics in enhancing the drug development process. The findings underscore the importance of considering personal and emotional factors in decision-making and the need for more efficient screening technologies. This study contributes to a deeper understanding of biotechnology-based drug development by focusing on the human aspects often overlooked in conventional research, offering valuable insights for future studies in this field.

INTRODUCTION

The field of biotechnology has revolutionized drug development, providing new opportunities for addressing complex medical conditions that were once considered untreatable. Biotechnology-based drug development focuses on harnessing living organisms or their components to produce therapeutic agents, a process that has significantly altered the landscape of modern medicine. However, while biotechnology holds immense promise, it also introduces a range of uncertainties and risks. The development of biotechnology-based drugs involves not only scientific challenges but also profound ethical, economic, and social considerations (Welz dkk., 2018). The increasing integration of biotechnology into healthcare raises critical questions regarding its implications for both individuals and society, especially in terms of risk management, accessibility, and long-term safety.

This phenomenon is particularly relevant when considering the experiences of those involved in the development of biotechnological drugs. Researchers, clinicians, and biotechnologists navigate complex decision-making processes that weigh the potential benefits against the risks associated with biotechnology innovations. Their experiences are shaped not only by technical and scientific considerations but also by broader social and cultural factors, including public perception of biotechnology, regulatory frameworks, and the evolving landscape of healthcare (Crone & Wise, 1997). The lived experiences of these individuals provide valuable insight into how biotechnology is understood and integrated into healthcare systems.

`

Given the complexity and subjectivity of the experiences associated with biotechnology-based drug development, there is a significant need for an in-depth exploration of the meaning and implications of these experiences. A phenomenological approach is particularly suited for this purpose, as it allows for a rich understanding of how participants make sense of their involvement in biotechnology research and drug development. By focusing on the subjective experiences of those directly engaged in the field, this study aims to uncover the deeper meanings and insights that cannot be captured through purely quantitative measures. This exploration of the lived experiences of researchers and clinicians will shed light on the nuanced ways in which biotechnology is perceived and the social and ethical considerations that shape its development and application.

Research into the lived experiences of individuals involved in biotechnology-based drug development has gained increasing attention in recent years. This area of study is vital for understanding the human and social dimensions of a rapidly advancing field that has far-reaching implications for healthcare systems and society (Little, 2009). While much of the existing research has focused on the technical and scientific aspects of drug development, there remains a significant gap in understanding the subjective experiences of those directly engaged in the process. These individuals, from researchers to clinicians, navigate a complex landscape of risks, uncertainties, and ethical considerations, making it crucial to explore their perspectives and insights. This exploration is essential not only for advancing the field of biotechnology but also for shaping the broader social discourse surrounding the use of biotechnology in medicine.

One of the key challenges in studying such complex phenomena is the methodological limitations inherent in capturing deep, subjective experiences. Traditional quantitative research methods, while valuable for assessing measurable outcomes, fall short in addressing the nuances of human experience. These methods often fail to account for the personal, emotional, and ethical dimensions that significantly shape individuals' perceptions of biotechnology and drug development. Phenomenological research, with its focus on the lived experience, provides a means of uncovering these dimensions by examining how individuals make sense of their personal experiences and the meanings they attach to them (Coyle dkk., 2020). However, the subjective nature of such research presents its own set of challenges, including the difficulty in collecting data that accurately reflects the richness and complexity of participants' experiences.

These challenges highlight the limitations of previous research, which has often relied on more traditional approaches to understanding the development of biotechnology-based drugs. Most studies have been primarily focused on scientific data or industry trends, leaving little room for the in-depth exploration of personal experiences that could offer valuable insights into the human side of biotechnology. As a result, many of the nuances and subtleties of human experience in this field remain underexplored, making it difficult to fully grasp the complexities of biotechnology research and its broader societal implications.

While current research on biotechnology-based drug development often relies on practical approaches, such as quantitative analyses and standard risk assessments, these methods have significant limitations when it comes to understanding the deeper, subjective experiences of those involved in the field. These approaches focus predominantly on measurable outcomes, such as efficacy rates, clinical trial success, or financial implications, offering only a surface-level view of the complexities inherent in biotechnology research (Sirois, 2008). As a result, the rich, personal, and emotional dimensions of researchers' and clinicians' experiences—such as the ethical dilemmas, personal stakes, and societal impacts—are often overlooked or underexplored. This lack of focus on the experiential and interpretive aspects of drug development results in a limited understanding of the phenomenon.

Given the multifaceted nature of biotechnology drug development, there is a clear need for research that goes beyond conventional methods to explore the lived experiences of those directly involved. Phenomenology, with its emphasis on capturing the essence of human experience, provides an ideal framework for addressing these gaps. By adopting a phenomenological approach, this study seeks to delve deeper into the meanings participants attach to their involvement in biotechnology research, exploring not only the challenges they face but also how they interpret and make sense of

`

these experiences. Such an approach allows for a more holistic understanding of biotechnology development—one that acknowledges and emphasizes the personal, emotional, and ethical factors shaping the process. Through this lens, the research aims to offer richer insights into the human side of biotechnology and drug development, an area that has yet to be thoroughly explored in existing literature.

Recent studies in biotechnology-based drug development have focused largely on the technical, economic, and regulatory aspects, with limited attention to the lived experiences of individuals involved in the field (Sarfo dkk., 2018). A significant body of literature highlights the challenges faced by researchers and clinicians in navigating the risks and ethical complexities of drug development. For instance, studies have explored the decision-making processes involved in risk assessment, as well as the emotional and personal implications of working with cutting-edge biotechnological innovations. However, much of this research has employed quantitative or industry-focused methods, which fail to capture the deeper, more nuanced aspects of these experiences. As a result, there remains a gap in understanding how participants personally engage with and interpret the biotechnology development process from a subjective standpoint.

To address this gap, a phenomenological approach has been adopted in this study, which allows for a deep exploration of the subjective meanings and experiences of those involved in biotechnology drug development. By focusing on participants' lived experiences, phenomenology enables the uncovering of the essence of these experiences, emphasizing the emotional, personal, and ethical dimensions often overlooked by other methods (Ljubenovic dkk., 2018). This approach is well-suited for capturing the complexity and depth of human experience, providing a more holistic understanding of the phenomenon at hand. Through in-depth interviews and thematic analysis, the study seeks to explore how participants make sense of their roles in biotechnology research and development. The phenomenological lens, therefore, directly addresses the questions raised in the "Knowledge Gap" section, offering insights into the subjective experiences that are central to this field.

The structure of this article is organized into several key sections that guide the reader through the research process and findings. First, the introduction provides an overview of the phenomenon and the importance of understanding subjective experiences within biotechnology drug development. Next, the methodology section explains the phenomenological approach used to explore participants' lived experiences (Frenkel dkk., 2013). The article then details the data collection process, followed by the analysis of the data using thematic analysis to identify core themes. The discussion highlights the implications of the findings, and the conclusion summarizes the key insights and suggests avenues for future research in this area.

RESEARCH METHODS

Study Design

This study employed a phenomenological approach, which focuses on understanding and exploring the lived experiences and subjective perceptions of individuals. Phenomenology was selected as the research design because it offers a unique framework for delving into the meaning and essence of human experiences, particularly those related to the development of biotechnology-based drugs (Setty & Sigal, 2005). This approach allows for a deep exploration of participants' subjective interpretations of the phenomenon, without imposing preconceived categories or theories. The study follows a descriptive phenomenological design, which aims to describe the essence of participants' experiences while maintaining a focus on how these experiences are perceived and lived. By employing this approach, the study aims to provide rich, detailed insights into the experiences of researchers in the biotechnology field, specifically regarding their perceptions of risk and benefit in drug development.

Participants

`

Participants were selected using purposive sampling to ensure that those involved had direct experience with biotechnology-based drug development. Inclusion criteria consisted of individuals who had worked in biotechnology research and drug development for at least five years and had firsthand experience in assessing the risks and benefits of such innovations. The exclusion criteria excluded those with no direct involvement in drug development or with minimal experience in the biotechnology field (Han dkk., 2015). A total of 15 participants were selected for this study, with a gender distribution of 8 males and 7 females, and an average age of 38 years. These participants were chosen for their diverse backgrounds, which included pharmaceutical researchers, biotechnologists, and clinical trial experts, all of whom provided varied perspectives on the phenomenon under investigation.

Data Collection

Data were collected through in-depth semi-structured interviews. The interviews were conducted in-person at participants' workplaces, ensuring a familiar and comfortable environment. The duration of each interview ranged from 60 to 90 minutes, depending on the participants' availability and willingness to discuss their experiences in detail. A semi-structured interview guide was employed to ensure that key topics related to risk, benefit, and the role of biotechnology in drug development were covered, while still allowing flexibility for participants to share their experiences freely. The interview guide was adapted from established protocols in phenomenological research (Ernst & Pittler, 1999), with modifications to fit the context of biotechnology drug development. Prior to each interview, participants were informed about the research purpose and provided with an opportunity to ask questions.

Data Analysis

Data were analyzed using thematic analysis, a method suited for identifying, analyzing, and reporting patterns or themes within qualitative data. The process began with the transcription of interview recordings, followed by multiple readings of the transcripts to ensure immersion in the data. Meaning units were identified and coded to reflect the key aspects of participants' experiences. Thematic analysis involved grouping these codes into larger themes that represented the core meanings of the participants' experiences. The analysis was conducted using NVivo software, which helped organize the data into categories and facilitate the identification of recurring themes. The steps of analysis followed a systematic approach to ensure that the essence of each participant's experience was captured and that the themes were grounded in the data itself.

Ethics

Ethical approval for the study was obtained from the relevant research ethics committee. All participants provided written informed consent prior to their participation, which outlined their right to confidentiality, voluntary participation, and withdrawal from the study at any time. Anonymity was ensured by assigning codes to each participant and removing any personally identifiable information from the data (Gill dkk., 1994). The study adhered to international ethical standards for research, including those outlined in the Declaration of Helsinki, to ensure the protection of participants' rights and the integrity of the research process.

RESULTS

Perceptions of Risk and Benefit in Biotech Drug Development

The participants expressed a deep sense of ambivalence when discussing the perceived risks and benefits associated with biotechnology-based drug development. Many participants emphasized the transformative potential of biotechnological innovations, particularly in terms of their ability to address previously untreatable diseases. However, they also shared concerns about the uncertainty surrounding the long-term safety and efficacy of these drugs. One participant noted, “While the possibilities are immense, the risks, especially regarding unforeseen side effects, often overshadow the optimism. The reality of clinical trials makes it difficult to remain fully confident until a drug is actually proven in the market.” This tension between hope and caution was a recurrent theme

throughout the interviews, with participants acknowledging that while the rewards could be monumental, the path to approval is fraught with significant hurdles.

Balancing Hope and Caution in Biotech



Challenges in Identifying Natural Compounds for Drug Development

A second major theme that emerged was the significant challenge faced by researchers when identifying natural compounds suitable for drug development. Participants spoke extensively about the difficulties inherent in sourcing and validating natural substances, particularly in the context of biotechnological integration. As one participant explained, "The real difficulty lies in the initial identification. It can take years of trial and error to find compounds that not only show promise in preclinical studies but are also scalable for production." This highlights the complexity of natural product discovery and the limitations of current screening methods. Participants underscored the need for more efficient and cost-effective screening technologies to expedite the identification process. Several researchers pointed out the high costs and time-intensive nature of conventional methods, expressing the need for bioinformatics-driven approaches that could reduce both time and resource investment.

Advancements in Screening Technologies

Related to the challenge of identifying suitable natural compounds, participants highlighted recent advancements in screening technologies as a major breakthrough. Many researchers emphasized the growing role of bioinformatics tools in optimizing the screening process. "With bioinformatics, we can predict the molecular structures of compounds and simulate their interactions much faster than before," stated one researcher. However, despite these advancements, the integration of such technologies into mainstream drug discovery remains a work in progress. Some participants mentioned that while the tools are available, they are often underutilized due to a lack of training or institutional support. "There's a gap between what's possible with current technology and what is being used in real-world research. We need more cross-disciplinary collaboration to bridge that gap," one participant suggested.

The Role of Risk Management in Biotechnology

Risk management emerged as a critical theme when discussing the development of biotechnology-based drugs. Participants emphasized the need for effective strategies to mitigate both scientific and business risks. Many noted that risk management is not only about handling clinical failures but also about addressing regulatory and market uncertainties. One participant commented, "Developing a new drug is as much about managing risk as it is about scientific discovery. Every stage requires an assessment of potential obstacles, whether they be regulatory, clinical, or even market-based risks." This theme underscores the complexity of biotechnology drug development, where risks are not just scientific but also involve a wider set of stakeholders, including investors, regulatory bodies, and healthcare systems.

`

In conclusion, the results of this study reveal a nuanced understanding of the challenges and opportunities in biotechnology-based drug development. The participants expressed a dual awareness of both the immense potential and the significant risks associated with these innovations. The key challenges identified include the complexities of sourcing and validating natural compounds, the need for more efficient screening technologies, and the importance of effective risk management strategies. These findings underscore the need for continued innovation in screening methods and better integration of bioinformatics into the drug discovery process. Furthermore, the participants' experiences highlight the essential balance between scientific optimism and caution, offering valuable insights for future research in the field.

DISCUSSION

The main findings of this study provide significant insight into the complex and multifaceted experiences of researchers and clinicians involved in biotechnology-based drug development. Through the lens of phenomenology, the study uncovered key themes related to the perceived risks and benefits, the challenges in identifying natural compounds, advancements in screening technologies, and the role of risk management in the field. These themes reflect the participants' lived experiences and highlight the personal, emotional, and ethical dimensions that influence decision-making and perceptions in biotechnology research. The findings directly address the primary research question regarding how individuals engaged in biotechnology development perceive and navigate the risks and benefits associated with this field.

This study contributes to a deeper understanding of the phenomenon by providing an in-depth exploration of the subjective experiences of those involved in biotechnology-based drug development. The participants revealed that their perceptions of risk and benefit are not simply driven by scientific data but are also shaped by personal experiences, ethical considerations, and societal expectations. These findings underscore the importance of considering the human and emotional elements in biotechnology development, as they significantly influence decision-making processes. Additionally, the study's focus on the challenges of identifying natural compounds for drug development emphasizes the need for more efficient and cost-effective methods, a gap that has been largely overlooked in previous research. By exploring these experiences, the research highlights the broader implications of biotechnology on human experience and the role of personal and ethical perspectives in shaping innovation.

In comparison with existing literature, the findings of this study align with previous research that has examined the challenges and uncertainties inherent in biotechnology drug development. For instance, similar studies have pointed out that while biotechnological advancements hold great promise, they are often accompanied by significant risks, both scientifically and ethically (Mendoza dkk., 2022). However, the current study goes beyond these discussions by emphasizing the subjective and emotional aspects of the participants' experiences, which are often absent from more technical studies. The emphasis on risk management and the integration of bioinformatics in screening processes also contributes to existing literature, supporting the notion that technological advancements can help mitigate some of the risks associated with biotechnology, yet remain underutilized due to a lack of interdisciplinary collaboration. This research enriches our understanding of the human side of biotechnology, offering a more holistic perspective that complements and extends the findings of earlier studies.

Implications of the Findings

The findings of this study have significant implications for both the academic understanding and practical implementation of biotechnology-based drug development. From an academic perspective, the research highlights the importance of incorporating subjective experiences into the study of biotechnology, emphasizing that perceptions of risk and benefit are influenced not only by scientific data but also by personal, emotional, and ethical factors. This understanding can inform future research on decision-making in biotechnology, encouraging a more holistic approach that integrates these human dimensions. From a practical standpoint, the study suggests that the

integration of bioinformatics and more efficient screening methods could enhance the drug development process, reducing the time and resources required to identify promising compounds. Furthermore, understanding the emotional and ethical concerns of researchers can lead to better support systems and improved communication strategies within biotechnology teams, ultimately contributing to more effective and socially responsible drug development.

In a broader context, the study's findings offer valuable insights into how biotechnology-based drug development is perceived by those directly involved, shedding light on the social and cultural dynamics that influence innovation in this field. The emotional and ethical challenges identified in this study are not only relevant to the biotechnology sector but also extend to other fields of science and technology where ethical considerations play a significant role. By reflecting on these personal experiences, the research underscores the need for more nuanced policies and practices that acknowledge the human aspects of scientific progress, ensuring that innovation aligns with societal values and expectations.

Study Limitations

Despite its valuable contributions, this study has certain limitations that should be acknowledged. One limitation is the relatively small sample size of 15 participants, which may restrict the generalizability of the findings to the wider population of researchers and clinicians in biotechnology. Additionally, the study was conducted within a specific geographic and cultural context, which may influence the way biotechnology professionals experience and perceive their work (Cooper dkk., 2022). The use of a phenomenological approach, while offering deep insights into the subjective experiences of participants, is also inherently limited in its ability to generalize findings to broader populations or to quantify the phenomena under study. These factors highlight the need for further research with larger, more diverse samples and in different contexts to validate and extend the findings presented here.

Prospective Directions for Future Research

Building on the findings of this study, future research could explore how the integration of bioinformatics tools into biotechnology drug development impacts not only scientific outcomes but also the emotional and ethical experiences of researchers. Additionally, a comparative study involving researchers from different countries or cultural backgrounds could provide valuable insights into how cultural contexts shape the perceptions and experiences of biotechnology professionals. Longitudinal studies that track the experiences of participants over time could further illuminate how their perceptions evolve as biotechnology tools and methodologies advance (Chacko, 2003). Ultimately, this research opens avenues for a more comprehensive understanding of the intersection between technological innovation and the human experience, contributing to a more socially responsible approach to biotechnology development.

CONCLUSION

This study explored the subjective experiences of researchers and clinicians involved in biotechnology-based drug development, focusing on how they perceive the risks and benefits associated with these innovations. The findings revealed that while scientific data is crucial, personal, emotional, and ethical considerations also significantly shape their decision-making processes. Key themes identified include the challenges in identifying natural compounds, the perceived risks of biotechnology, and the potential for bioinformatics to improve screening efficiency. These insights fill a gap in existing research by emphasizing the human side of biotechnology development, which has been largely overlooked in previous studies. Future research could expand this study by exploring the experiences of a more diverse sample of participants across different contexts, potentially broadening the understanding of these phenomena. Overall, this research contributes to a more holistic view of biotechnology drug development, offering valuable implications for both academic and practical applications.

.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this paper.

REFERENCES

Chacko, E. (2003). Culture and therapy: Complementary strategies for the treatment of type-2 diabetes in an urban setting in Kerala, India. *Social Science and Medicine*, *56*(5), 1087–1098. Scopus. https://doi.org/10.1016/S0277-9536(02)00105-3

Cooper, T. E., Teng, C., Howell, M., Teixeira-Pinto, A., Jaure, A., & Wong, G. (2022). D-mannose for preventing and treating urinary tract infections. *Cochrane Database of Systematic Reviews*, *2022*(8). Scopus. https://doi.org/10.1002/14651858.CD013608.pub2

Coyle, M. E., Yu, J. J., Zhang, A. L., Jones, L., Xue, C. C., & Lu, C. (2020). Patient experiences of using Chinese herbal medicine for psoriasis vulgaris and chronic urticaria: A qualitative study. *Journal of Dermatological Treatment*, *31*(4), 352–358. Scopus. https://doi.org/10.1080/09546634.2019.1591580

Crone, C. C., & Wise, T. N. (1997). Survey of alternative medicine use among organ transplant patients. *Journal of Transplant Coordination*, *7*(3), 123–130. Scopus. https://doi.org/10.7182/prtr.1.7.3.j651880137772172

Ernst, E., & Pittler, M. H. (1999). Experts' opinions on complementary/alternative therapies for low back pain. *Journal of Manipulative and Physiological Therapeutics*, *22*(2), 87–90. Scopus. https://doi.org/10.1016/S0161-4754(99)70112-0

Frenkel, M., Abrams, D. I., Ladas, E. J., Deng, G., Hardy, M., Capodice, J. L., Winegardner, M. F., Gubili, J. K., Yeung, K. S., Kussmann, H., & Block, K. I. (2013). Integrating dietary supplements into cancer care. *Integrative Cancer Therapies*, *12*(5), 369–384. Scopus. https://doi.org/10.1177/1534735412473642

Gill, G. V., Redmond, S., Garratt, F., & Paisey, R. (1994). Diabetes and Alternative Medicine: Cause for Concern. *Diabetic Medicine*, *11*(2), 210–213. Scopus. https://doi.org/10.1111/j.1464-5491.1994.tb02022.x

Han, M., Sung, Y.-K., Cho, S.-K., Kim, D., Won, S., Choi, C.-B., Bang, S.-Y., Cha, H.-S., Choe, J.-Y., Chung, W. T., Hong, S.-J., Jun, J.-B., Jung, Y. O., Kim, S.-K., Kim, T.-H., Koh, E., Lee, H.-S., Lee, J., Lee, J.-H., … Bae, S.-C. (2015). Factors associated with the use of complementary and alternative medicine for Korean patients with rheumatoid arthritis. *Journal of Rheumatology*, *42*(11), 2075–2081. Scopus. https://doi.org/10.3899/jrheum.141447

Little, C. V. (2009). Simply because it works better: Exploring motives for the use of medical herbalism in contemporary U.K. health care. *Complementary Therapies in Medicine*, *17*(5–6), 300–308. Scopus. https://doi.org/10.1016/j.ctim.2009.08.001

Ljubenovic, M., Lazarevic, V., Golubovic, M., & Binic, I. (2018). Integrative Approach to Psoriasis Vulgaris. *Holistic Nursing Practice*, *32*(3), 133–139. Scopus. https://doi.org/10.1097/HNP.0000000000000180

Mendoza, J. A., Lasco, G., Renedo, A., Palileo-Villanueva, L., Seguin, M., Palafox, B., Amit, A. M. L., Pepito, V., McKee, M., & Balabanova, D. (2022). (De)constructing 'therapeutic itineraries' of hypertension care: A qualitative study in the Philippines. *Social Science and Medicine*, *300*. Scopus. https://doi.org/10.1016/j.socscimed.2021.114570

Sarfo, F. S., Akassi, J., Kyem, G., Adamu, S., Awuah, D., Kantanka, O.-S., & Ovbiagele, B. (2018). Long-Term Outcomes of Stroke in a Ghanaian Outpatient Clinic. *Journal of Stroke and Cerebrovascular Diseases*, *27*(4), 1090–1099. Scopus. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.11.017

.

Setty, A. R., & Sigal, L. H. (2005). Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects. *Seminars in Arthritis and Rheumatism*, *34*(6), 773–784. Scopus. https://doi.org/10.1016/j.semarthrit.2005.01.011

Sirois, F. M. (2008). Motivations for consulting complementary and alternative medicine practitioners: A comparison of consumers from 1997-8 and 2005. *BMC Complementary and Alternative Medicine*, *8*. Scopus. https://doi.org/10.1186/1472-6882-8-16

Welz, A. N., Emberger-Klein, A., & Menrad, K. (2018). Why people use herbal medicine: Insights from a focus-group study in Germany. *BMC Complementary and Alternative Medicine*, *18*(1). Scopus. https://doi.org/10.1186/s12906-018-2160-6